Results 181 to 190 of about 186,761 (273)

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

Alimentary Pharmacology &Therapeutics, EarlyView.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber   +8 more
wiley   +1 more source

Immunotherapy induced sarcoidosis in a 47-year-old female with stage IIIC cervical cancer on pembrolizumab: A case report. [PDF]

Gynecol Oncol Rep
O'Neill H, Bruegl A.
europepmc   +1 more source

Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies [PDF]

, 2018
Bradley, Jeffrey D, et al,
core   +1 more source

Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors

British Journal of Haematology, EarlyView.
Summary Immune checkpoint inhibitors (ICIs) have shown to be effective in the treatment of Hodgkin lymphoma (HL). ICI treatment is associated with the occurrence of a series of immune‐related adverse events (irAEs). We conducted an ambispective observational study on 96 patients with relapsed/refractory HL treated with ICIs to determine the incidence ...
Lisa Argnani, Vittorio Stefoni, Beatrice Casadei, Carla Pelusi, Valentina Lo Preiato, Uberto Pagotto, Anna Buganè, Cinzia Pellegrini, Alessandro Broccoli, Pier Luigi Zinzani   +9 more
wiley   +1 more source

Bilateral Superior Branch Retinal Artery Occlusions in a Patient on Pembrolizumab. [PDF]

Int Med Case Rep J
Zhao CS, Mruthyunjaya P, Narala R, DeBoer CMT.   +3 more
europepmc   +1 more source

A Case of Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus Achieving Pathologic Complete Response Following Combination Therapy With Lenvatinib and Pembrolizumab. [PDF]

IJU Case Rep
Takayama H, Sano T, Hirao K, Motoki Y, Taniguchi H, Yanishi M, Uchida K, Kinoshita H.   +7 more
europepmc   +1 more source

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta‐analysis

BJU International, EarlyView.
Objective To evaluate the concordance between clinical complete response (cCR) and pathological complete response (pCR) in muscle‐invasive bladder cancer (MIBC) to assess the surrogacy and prognostic value of cCR for guiding bladder‐sparing strategies.
Navid Roessler, Marcin Miszczyk, Paolo Gontero, Alessandro Dematteis, Keiichiro Miyajima, Shota Inoue, Katharina Oberneder, Markus von Deimling, Victor M. Schuettfort, Malte W. Vetterlein, Bernadett Szabados, Pawel Rajwa, Pierre I. Karakiewicz, Jeremy Yuen‐Chun Teoh, Margit Fisch, Shahrokh F. Shariat   +15 more
wiley   +1 more source

How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study. [PDF]

Future Oncol
Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Homet Moreno B, Beaumont JL, Purnajo I, McManus S, Powles T.   +24 more
europepmc   +1 more source

Top 5 Advances in the Last 50 Years: Malignant Gastric and Esophageal Surgery

World Journal of Surgery, EarlyView.
Luís Santos Castro, Lorenzo Ferri
wiley   +1 more source

A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancer

BJU International, EarlyView.
Objectives To establish a UK consensus vision of a standardised genomic testing pathway in unresectable/metastatic urothelial cancer (mUC) with clear roles and responsibilities for multidisciplinary team (MDT) members and molecular pathology laboratory teams, and to agree how the pathway must evolve to accommodate emerging innovations.
Syed A. Hussain, Amarnath Challapalli, Simran Gill, Michael Hubank, Hannah Markham, Philippe Tanière, Simon Wyatt, Robert Jones   +7 more
wiley   +1 more source